Integrative Oncology Breakthrough: How Combining Eastern and Western Medicine Enhances Cancer Immunotherapy
Cancer treatment is entering a new era where the precision of Western immunotherapy meets the ancient wisdom of Eastern medicine. At the recent 2026 Spring Academic Conference of the Korean Society of Oncology, experts presented groundbreaking research demonstrating how integrative oncology—the strategic combination of traditional Korean medicine (TKM) and modern Western oncology—can enhance immune modulation and improve patient outcomes. With new data showing promising synergy between acupuncture, herbal formulations and checkpoint inhibitors, this approach is poised to redefine personalized cancer care.
Understanding Integrative Oncology: Bridging Two Worlds
Integrative oncology is not a new concept, but recent advancements in immunology and pharmacology have provided the scientific rigor to validate its potential. The core principle revolves around multilayered immune modulation: while Western therapies like PD-1/PD-L1 inhibitors target specific immune checkpoints, TKM—including acupuncture, herbal medicines (e.g., Hwangryun-haedok-tang), and moxibustion—can stimulate broader immune responses, reduce treatment-related toxicity, and enhance quality of life.
What Is Multilayered Immune Modulation?
A strategy that combines multiple therapeutic approaches to:
- Enhance immune activation (e.g., increasing cytokine production, improving T-cell function)
- Reduce immune suppression (e.g., mitigating side effects like fatigue or myelosuppression)
- Target tumor microenvironments (e.g., reducing angiogenesis or metabolic support for cancer cells)
2026 Korean Society of Oncology: The Science Behind the Synergy
The conference highlighted three key areas where integrative approaches are showing clinical promise:
1. Acupuncture for Pain and Immune Support in Cancer Patients
Acupuncture has long been used in Korea to manage pain and nausea in cancer patients. New research presented at the conference revealed its immunomodulatory effects, particularly in reducing inflammation and improving lymphocyte counts during chemotherapy. A secondary analysis of the PRACXIS trial (conducted at both university and public hospitals in the U.S.) found that patients receiving acupuncture alongside standard oncology care experienced:
- A 20% reduction in opioid use for pain management
- Improved natural killer (NK) cell activity by 15–25%
- Fewer episodes of chemotherapy-induced neutropenia
Source: Yeung et al. (2026), “Effects of Acupuncture for Pain Management among Inpatients with Cancer”
2. Herbal Formulations as Adjuvants to Immunotherapy
Traditional Korean herbal medicines, such as Hwangryun-haedok-tang (a decoction used for immune support), are being studied for their ability to enhance the efficacy of PD-1 inhibitors. Preliminary data suggest that certain compounds in these herbs may:
- Increase T-cell infiltration into tumors by modulating the gut microbiome
- Reduce immune-related adverse events (irAEs) like colitis or dermatitis
- Provide radioprotective effects during radiation therapy
Note: While promising, these findings are still in early-phase clinical trials. Large-scale studies are needed to confirm safety, and efficacy.
3. Moxibustion and Immune System Regulation
Moxibustion, a TKM practice involving the burning of mugwort near the skin, has been shown to stimulate systemic immune responses. Research presented at the conference indicated that moxibustion may:
- Elevate interleukin-2 (IL-2) and interferon-gamma (IFN-γ) levels, key cytokines for anti-tumor immunity
- Improve circulatory function in patients with cancer-related fatigue
- Serve as a non-pharmacological alternative for managing side effects like peripheral neuropathy
Dr. Yu Hwa-seung: “Evidence-Based Integration for Public Health Impact”
In a keynote address, Dr. Yu Hwa-seung, newly appointed president of the Korean Society of Oncology, emphasized the importance of evidence-based integrative oncology to improve access and outcomes for all patients. “The goal is not to replace Western medicine but to optimize its effects through scientifically validated complementary approaches,” he stated. Dr. Yu highlighted three priorities for the field:
“We must standardize protocols for combining TKM and Western therapies, ensure rigorous clinical trials, and educate both patients and providers about the benefits—and limitations—of integrative care.”
Dr. Yu also called for greater collaboration between Korean and international researchers to accelerate global adoption of these strategies.
Frequently Asked Questions About Integrative Oncology
Q: Is integrative oncology safe?
A: When administered by trained professionals and combined with evidence-based protocols, integrative oncology can be safe. However, herbal medicines may interact with chemotherapy or immunotherapy, so patients must consult their oncologist before starting any complementary therapy. Always choose providers with expertise in both oncology and TKM.
Q: Are these treatments covered by insurance?
A: Coverage varies by country and region. In South Korea, acupuncture and certain TKM treatments are partially reimbursed under the National Health Insurance Service for cancer patients. In the U.S., Medicare and private insurers may cover acupuncture for pain management but rarely reimburse herbal medicines. Patients should check with their providers and insurers before proceeding.
Q: Can integrative oncology cure cancer?
A: No current evidence suggests integrative oncology can cure cancer alone. However, it may enhance the effectiveness of conventional treatments, improve quality of life, and reduce side effects. The focus is on complementing, not replacing, standard therapies.
5 Key Takeaways from the 2026 Korean Oncology Conference
- Synergistic Effects: Combining acupuncture, herbal medicines, and immunotherapy may lead to better immune responses and fewer side effects than either approach alone.
- Pain and Symptom Management: Acupuncture and moxibustion offer non-opioid alternatives for managing cancer-related pain, nausea, and fatigue.
- Growing Evidence: Early-phase trials show promise, but large-scale, randomized controlled studies are needed to confirm long-term benefits.
- Global Potential: Integrative oncology strategies developed in Korea could inform similar approaches worldwide, particularly in regions where TKM or traditional Chinese medicine (TCM) are widely used.
- Patient-Centered Care: The goal is to personalize treatment plans, balancing efficacy with quality of life.
The Future: Personalized and Integrative Cancer Care
As research in integrative oncology advances, we can expect:
- Biomarker-driven protocols: Using genetic and microbiome profiling to tailor TKM and Western therapies to individual patients.
- Expanded clinical trials: More rigorous studies comparing integrative approaches to standard care in diverse populations.
- Policy changes: Greater recognition of integrative oncology in national cancer treatment guidelines.
- Education initiatives: Training programs for oncologists and TKM practitioners to collaborate safely and effectively.
The integration of Eastern and Western medicine represents a paradigm shift in oncology—not as a replacement for modern science, but as a powerful complement. As Dr. Yu Hwa-seung noted, the future of cancer care lies in bridging traditions with innovation to deliver the best possible outcomes for patients.
Worth a look